| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA542: Cabozantinib for untreated advanced renal cell carcinoma |
|
Medicine details |
|
| Medicine name | cabozantinib (Cabometyx®) |
| Formulation | 20 mg, 40 mg, 60 mg film-coated tablet |
| Reference number | 3467 |
| Indication | Treatment of advanced renal cell carcinoma in treatment-naïve adults with intermediate or poor risk |
| Company | Ipsen Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 19/04/2018 |
| NICE guidance | TA542: Cabozantinib for untreated advanced renal cell carcinoma |